| Bioactivity | AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC50=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity[1]. | ||||||||||||
| In Vivo | AL 8697 (1-30 mg/kg; p.o.; once daily for 10 days) dose-dependently decreases the oedema in right and left paws[1]. Animal Model: | ||||||||||||
| Name | AL 8697 | ||||||||||||
| CAS | 1057394-06-5 | ||||||||||||
| Formula | C21H21F3N4O | ||||||||||||
| Molar Mass | 402.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Balagué C, et al. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br J Pharmacol. 2012 Jun;166(4):1320-32. |
AL 8697
CAS: 1057394-06-5 F: C21H21F3N4O W: 402.41
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhi
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.